{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-056665","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2025-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.503814+00:00","generated_at":"2026-05-19T22:20:04.775738+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Kiniksa details Phase 2/3 trial design for KPL-387 in recurrent pericarditis; initiation mid-2025","bullets":["Phase 2/3 trial: dose-focusing portion enrolls up to ~80 patients; pivotal portion up to ~85.","Primary endpoint: time to treatment response at Week 24 (Phase 2) and time to first recurrence (Phase 3).","Phase 1 single ascending dose data support monthly subcutaneous dosing with liquid formulation.","Phase 2 data expected in second half of 2026.","Corporate presentation at Jefferies 2025 Global Healthcare Conference at 12:50 pm ET on June 5."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-056665","json":"https://secwatch.observer/filing/0001104659-25-056665.json","markdown":"https://secwatch.observer/filing/0001104659-25-056665.md","text":"https://secwatch.observer/filing/0001104659-25-056665.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465925056665/0001104659-25-056665-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465925056665/tm2517185d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T22:20:04.775738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}